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Decision making in asthma therapy—what is
important in clinical practice?Although the prevalence of asthma is rising around
the world, the disease remains poorly controlled
despite the availability of highly effective anti-
asthma therapies. Failure to follow asthma man-
agement guidelines, patient non-compliance with
therapy, and inhaler misuse (particularly pres-
surised metered dose inhalers (pMDIs)), contribute
to this lack of disease control. The implementation
of asthma management guidelines is improving, but
until these guidelines are adhered to, asthma will
often remain poorly controlled. As it is unlikely that
asthma therapy will improve significantly in the
near future, advances in inhaled drug delivery have
become an important aspect of improving asthma
management. An inhaler device which improves
patient compliance would represent a major step
forward in asthma management. Dry powder
inhalers (DPIs) preclude the need to coordinate
inspiration with activation, are easy and conveni-
ent to use and are environmentally friendly.
A satellite symposium held during the 13th
Annual Congress of the European Respiratory
Society in Vienna Austria, from 27 to 31 September
2003, reviewed several issues surrounding the
management of patients with asthma. In particular,
how to measure the effects of inhaled corticoster-
oids (ICSs) in clinical studies; how to assess long-
term asthma control in clinical practice; the
importance of the inhaler device and how this has
recently been improved; new data on key para-
meters for effective use of DPI systems and; how to
achieve good compliance with inhaled asthma
therapy were reviewed.
Asthma is a highly complex inflammatory disease
of the airways involving many inflammatory cells
and their mediators. ICSs are the gold standard
anti-inflammatory therapy for asthma and have
been studied in numerous different clinical trial
designs such as long-term comparative studies,ee front matter r 2004 Elsevier Ltd. All rights reserv
med.2004.07.008retrospective steroid tapering and mortality stu-
dies, combination studies and dose–response stu-
dies. The effectiveness of ICSs has also been
assessed using allergen challenge models and by
measuring their effect(s) on airway hyper-respon-
siveness and exhaled nitric oxide (NO) concentra-
tions. Results have shown that ICSs are more
effective in controlling asthma than b-agonists or
leukotriene agonists. Steroid tapering induces
asthma exacerbations, whilst the regular use of
low doses of ICSs prevents death from asthma. ICSs
show a modest dose response for lung function,
symptom control and oral corticosteroid use, are
effective in reducing airway hyper-responsiveness
to various stimuli, and reduce exhaled NO concen-
trations and the number and activation state of a
wide variety of inflammatory cells. Finally, using
allergen challenge models even single doses of ICSs
have profound inhibitory effects on the late
asthmatic reaction.
Although highly effective treatments for asthma
are readily available (e.g. ICSs and long-acting b2-
agonists), the prevalence and incidence of asthma
continues to rise around the world and the disease
remains poorly controlled. Asthma control may be
improved by the use of assessment tools which
monitor asthma control and detect exacerbations
before the alteration of functional parameters and
the occurrence of symptoms. Effective monitoring
of asthma control would enable clinicians to
increase corticosteroid dose or to stop corticoster-
oid tapering before symptoms occur. Tools to assess
asthma control must be reproducible, acceptable
to patients, non-invasive, and suitable for long-
term use. Tools currently used include clinical
parameters (e.g. symptom scores, nocturnal awa-
kenings and rescue medication use), lung function,
questionnaires, bronchial hyper-responsiveness,
sputum eosinophilia and exhaled NO. Sputumed.
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been shown to be predictive of asthma exacerba-
tions as changes in these parameters occur before
symptom manifestation. Therefore, monitoring
exhaled NO and sputum eosinophilia is useful for
preventing exacerbations from occurring in the first
instance and may help to achieve asthma control in
the long-term.
Lack of asthma control may be caused by many
factors such as non-implementation of asthma
management guidelines and patient non-compli-
ance with prescribed anti-asthma therapy. The
Global INitiative for Asthma (GINA) guidelines
defines asthma control and recommends therapeu-
tic strategies to attain control of the disease.
However, the guidelines are frequently not imple-
mented as they do suffer from many inherent
limitations. Treatment regimens should take into
account patients’ ‘real-life’ conditions in order to
realistically tackle the disease. Non-compliance
with therapy is another major reason why asthma
remains poorly controlled. The reasons for non-
compliance are complex and involve drug and non-
drug factors. In the non-drug category, inability to
use inhaler devices correctly is a common cause of
non-compliance.
pMDIs are the most frequently prescribed inhaler
devices despite the fact that they are inefficient,
difficult to use correctly, require extensive training
and retesting, have no inhalation control system,
no dose counter and are environmentally un-
friendly. In fact many patients and even health
care professionals cannot use them correctly,
mainly due to problems coordinating inhaler acti-
vation with inspiration. An inhaler device which
improves patient compliance would be a major
technological advancement. Criteria that may
improve patient compliance with an inhaler are:
correct use of the device by most patients,
accurate and consistent dose release (even at low
inspiratory flow), feedback to the patient that the
drug has been inhaled, ease and convenience of
device use, availability of cartridge refills and
overall confidence in the device. DPIs have several
advantages over pMDIs. They are breath-activated,
easy and convenient to use and environmentally
friendly.
There is no doubt that the type of inhaler is just
as important as the class of drug in the long-term
management of asthma. Improvements in inhaled
drug delivery will continue to be important in
improving asthma management. Three key para-
meters for successful inhaler use should be con-
sidered when evaluating existing or future DPI
devices: (1) compliance; (2) fine particle fraction
(FPF) with relatively little dependence on inspira-tory flow and; (3) clinical efficacy. A threshold
mechanism which controls for a minimal inspiratory
flow rate is desirable in order to support formation
of an optimal FPF and related lung deposition.
Additionally, in order to enhance patient compli-
ance a multi-dose DPI should feature a visual or
acoustic feedback of a successful inhalation. The
GINA guidelines recommend DPIs or breath-acti-
vated pMDIs for children older than 6 years. They
recommend that inhalers should be portable and
simple to operate, should not require power,
require minimal cooperation and coordination and
have minimal maintenance requirements. The
device itself should deliver an accurate and
consistent dose throughout its lifetime. It should
be easy and convenient to use, easy to teach,
deliver a range of molecules, have an accurate dose
counter, give patient feedback and be conveniently
carried, robust, visually appealing and chlorofluor-
ocarbon-free.
The articles that follow discuss several factors
that influence asthma management. The first
article (pp. S4–8) reviews the GINA guidelines as
to what constitutes asthma control, assesses the
current status of asthma control and discusses
many reasons why asthma, despite many pharma-
cological and technological advancements, remains
a poorly controlled disease. The article by Hansel
assesses the various clinical trial designs used to
assess the efficacy of ICSs in asthma. Magnan (pp.
S16–21) discusses many objective and subjective
tools used to measure asthma control and Richter
(pp. S22–27) describes the design features of the
Novolizers (VIATRIS, Germany). Clinical data ex-
amining the suitability of the Novolizers for use in
children, and data comparing the peak inspiratory
flow rate generated through the Novolizers and
the Turbuhalers in adults with moderate-to-severe
asthma or chronic obstructive pulmonary disease is
also reviewed. Virchow (pp. S28–34) reviews the
factors which influence clinician decisions regard-
ing which therapy and which device to prescribe to
patients. Finally, Crompton (pp. S35–40) reviews
the problems associated with pMDIs and DPIs
currently on the market, discusses factors likely
to improve patient compliance and examines how
the novel features of the Novolizers could improve
patient compliance.
The symposium concluded that inhaled therapy is
likely to remain predominant in the future and that
the type of inhaler is just as important as the class
of drug in the long-term management of asthma in
adults and children. Despite the availability of
highly effective anti-asthma therapies, the disease
remains poorly controlled, most likely due to non-
implementation of asthma management guidelines
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inhaler device which improves patient compliance
with therapy would be a major technological
advancement and an important step forward in
asthma management. The Novolizers is a multi-
dose refillable DPI with multiple feedback mechan-
isms, a unique trigger flow valve system, low
intrinsic resistance and particle size is relatively
independent of inspiratory flow rate. It is a device
which is tolerant of poor patient technique andhas many features which may improve patient
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